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Evaluation of VDR gene 
polymorphisms in Trypanosoma 
cruzi infection and chronic Chagasic 
cardiomyopathy
Daniel A Leon Rodriguez1, F David Carmona1, Clara Isabel González2,* & Javier Martin1,*
Vitamin D is an important modulator of the immune response. It acts over several immune cell types 
where the Vitamin D receptor (VDR) is expressed. Due to the high relevance of this signaling pathway, 
several studies have investigated the possible influence of genes involved in the metabolism of Vitamin 
D and its receptor in different human diseases. Here, we analyzed whether four single-nucleotide 
polymorphisms of the VDR gene (rs731236, rs7975232, rs1544410 and rs2228570) are involved in the 
susceptibility to infection by Trypanosoma cruzi and/or to chronic Chagas cardiomyopathy (CCC) in a 
Colombian endemic population for this parasite. Our results showed that the rs2228570*A allele is 
associated with CCC development (P = 4.46E−03, OR = 1.51). In summary, the data presented in this 
report suggest that variation within the VDR gene may affect the immune response against T. cruzi, 
increasing the probability of cardiac complications in infected individuals.
Vitamin D is an important modulator of the immune system1,2. This molecule is involved in both the innate 
and adaptive responses acting on a wide spectrum of immune cells, in which the Vitamin D receptor (VDR) is 
expressed3. VDR is a member of the nuclear receptor superfamily. Binding of this molecule with the activated 
form of Vitamin D (1,25(OH)2D3) causes its dimerization with retinoid X receptor (RXR), which control the 
transcription of specific genes by interacting with the RNA polymerase II1,4.
Chagas disease represents an infectious condition caused by the flagellated protozoan Trypanosoma cruzi that 
currently affects around 6 million people in Latin America5. Although infected people do not usually develop 
further complications after the acute phase of disease, up to one third will suffer from chronic Chagas cardiomy-
opathy (CCC) a condition that affects the life quality and could lead to premature death6,7. The exact causes of the 
differential disease outcomes are largely unknown, but increasing knowledge suggests that immune gene variants 
could play a relevant role by influencing the adequate inflammatory response against the parasitic invasion8–12. 
Consistent with this, several members of the inflammatory pathway have been recently associated with risk of 
infection by T. cruzi and/or development of CCC, including genes encoding for HLA class-II molecules (DRB1 
and DQB1), the chemokine receptor CCR5, interferon-gamma (IFN-γ ), tumor necrosis factor alpha (TNF-α ), 
migration inhibitory factor (MIF), and the interleukins IL-1, IL-12B, IL-17A, IL-18, among others13–20.
Due to the high relevance of Vitamin D and its receptor in the immune homeostasis, several studies have 
investigated the possible influence of genes involved in their metabolism in the development of autoimmune 
conditions and infectious diseases2,21. In this regard, some polymorphisms of the VDR gene have been reported 
to be associated with different outcomes in autoimmune and infectious diseases, especially in tuberculosis4,21.
Taking the above into consideration, we aimed to explore for the first time the possible implication of VDR 
genetic variation in Chagas disease susceptibility and clinical manifestation.
Results
The genotype frequencies of the four analyzed VDR variants did not deviate from Hardy-Weinberg equilibrium in 
the different subsets (P > 0.01), and their genotyping success rate was over 95%. The statistical power of this study 
is detailed in Table 1. The SNPs rs731236, rs7975232 and rs1544410 showed a relatively high LD in our study 
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population (Fig. 1). Particularly, rs731236 and rs1544410 had an r2 value = 0.93. On the contrary, rs2228570 had 
an r2 value < 0.10 with the other SNPs.
First, to analyze the possible implication of the VDR polymorphisms in the susceptibility to infection by T. 
cruzi, the allelic and genotypic frequencies of seronegative and seropositive individuals were compared (Table 2). 
No statistical significance was observed for rs731236, rs7975232 and rs1544410, indicating that these variants 
may not influence the risk of infection by T. cruzi in the studied population. On the other hand, the allele frequen-
cies of rs2228570 differed significantly between the seronegative and seropositive groups (P = 0.0287, OR = 0.81, 
95% CI = 0.67− 0.98). The minor allele rs2228570* A was overrepresented in the seronegative subset (45.41% vs. 
39.94%), suggesting a possible protective effect of this variant against infection by T. cruzi. However, the statistical 
significance was lost after correction for multiple testing (P = 0.1147).
Next, we evaluated the possible association between the VDR SNPs and the susceptibility to develop CCC. 
For that, we compared the allelic and genotypic frequencies of asymptomatic and CCC patients (Table 3). Similar 
to that observed in the previous analysis, no differences in the allele frequencies of both subgroups of patients 
Statistical power calculation
T. cruzi infection (436/547)* Chronic Chagasic cardiomyopathy (171/376)**
OR = 1.50 98% 82%
OR = 1.25 60% 35%
OR = 1.10 16% 10%
Table 1. Statistical power calculation of our study considering three different OR. The estimation was 
performed considering a prevalence of 1.44% and a minor allele frequency of 25%. * Analysis performed by 
using 436 seronegative vs. 547 seropositive individuals. * * Analysis performed by using 171 asymptomatic vs. 
376 chronic Chagas cardiomyopathy individuals.
Figure 1. R-Squared plot of analyzed VDR gene variants estimated by using expectation-maximization 
algorithm in Haploview V4.2.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:31263 | DOI: 10.1038/srep31263
were observed for the analyzed SNPs except for rs2228570 (P = 4.46E− 03, OR = 1.51, 95% CI = 1.14− 2.00). This 
association was maintained after controlling for multiple testing (P = 0.0178). In this case, the frequency of the 
rs2228570* A allele was reduced in the asymptomatic patients (34.41% vs. 42.47%), suggesting a putative protec-
tive role of this variant against CCC development.
On the other hand, a possible haplotypic effect of the studied VDR SNPs was also tested. Due to 
the high LD in this population (Fig. 1), only three haplotypes were observed in the studied individuals 
(rs731236|rs7975232|rs1544410: ACC, GAT and AAC). No evidence of association was observed for any haplo-
type in the different tests performed (seronegative vs. seropositive and asymptomatic vs. CCC, data not shown).
Discussion
In this study, four genetic variants of the VDR gene were tested for association with risk of infection by T. cruzi 
and/or development of CCC in a population from a Colombian endemic region of Chagas disease. Our data 
provides strong evidence that the VDR SNP rs2228570 is associated with CCC in infected individuals, as the odds 
of having the minor allele was significantly increased in symptomatic individuals as compared to asymptomatic 
patients. This polymorphism is located at the 5′ end of the VDR coding sequence. It has been reported that the 
presence of the minor allele originates an alternative starting transcription site, which leads to a longer isoform 
with a reduced transcription activity. Therefore, it has been proposed that the rs2228570 variant may affect the 
responsiveness to vitamin D22,23.
Vitamin D is a key molecule of the immune system. The active form of this compound seems to potentiate 
phagocytosis by macrophages and the production of antimicrobial peptides1,2. Additionally, it has been observed 
that it shifts the immune response from TH1/TH17 towards TH2 by inhibiting the production of IFN-γ , IL-12, 
IL-17, and IL-21, among other cytokines2. In Chagas disease, the infection by T. cruzi causes a coordinated 
immune response. That is, in the first line of defense, the innate response is initiated by dendritic cells and mac-
rophages, which produce IL-12 and TNF-α after recognizing the parasite. These cytokines activate natural killer 
cells that, in turn, enhance the production on IFN-γ . As a consequence, the parasite clearance is facilitated by 
shifting to a TH1 dominant response that controls the infection8. Hence, proinflammatory cytokines, such as 
IFN-γ , IL-12, IL-17 and TNF-α , are essential for controlling the parasite24–28. In addition, several studies have 
suggested that the persistence of T. cruzi in the organism is directly related to the development of severe compli-
cations in Chagas disease29–31. Our results are in agreement with the hypothesis that a stronger immune response 
may protect patients against the persistence of the parasite. Our data showed that the rs2228570* A allele, which 
allows the transcription of the enlarged VDR isoform, is more prevalent in CCC patients compared with asymp-
tomatic individuals. We speculate that vitamin D could influence the inflammatory response against T. cruzi by 
downregulating the expression of pro-inflammatory cytokines such as IFN-γ , IL-12 and IL-17. As a consequence, 
the parasitic persistence could be favored thus increasing the predisposition to develop cardiac complications 
SNP 1|2 Group (N)
Genotype. N (%)
MAF %
Allele test/Age
1|1 1|2 2|2 P PFDR OR [95% CI]
rs731236 G|A Seronegative (435) 42 (9.66) 166 (38.16) 227 (52.18) 28.74
Seropositive (545) 43 (7.89) 228 (41.83) 274 (50.28) 28.81 0.9024 0.9024 1.01 [0.83–1.24]
rs7975232 C|A Seronegative (436) 96 (22.02) 233 (53.44) 107 (24.54) 48.74
Seropositive (532) 97 (18.23) 291 (54.70) 144 (27.07) 45.58 0.2206 0.4412 0.88 [0.72–1.08]
rs1544410 T|C Seronegative (434) 39 (8.99) 166 (38.25) 229 (52.76) 28.11
Seropositive (535) 43 (8.04) 227 (42.43) 265 (49.53) 29.25 0.4677 0.6236 1.08 [0.88–1.33]
rs2228570 A|G Seronegative (436) 89 (20.41) 218 (50.00) 129 (29.59) 45.41
Seropositive (542) 83 (15.31) 267 (49.26) 192 (35.42) 39.94 0.0287 0.1147 0.81 [0.67–0.98]
Table 2.  Logistic regression analysis of VDR polymorphisms in seronegative and seropositive individuals 
including age as covariate.
SNP 1|2 Group (N)
Genotype. N (%)
MAF %
Allele test/Age
1|1 1|2 2|2 P PFDR OR [95% CI]
rs731236 G|A Asymptomatic (170) 17 (10.00) 69 (40.59) 84 (49.41) 30.29
CCC (375) 26 (6.93) 159 (42.40) 190 (50.67) 28.13 0.4406 0.4633 0.89 [0.67–1.19]
rs7975232 C|A Asymptomatic (164) 28 (17.07) 88 (53.66) 48 (29.27) 43.90
CCC (368) 69 (18.75) 203 (55.16) 96 (26.09) 46.33 0.4304 0.4633 1.12 [0.84–1.49]
rs1544410 T|C Asymptomatic (168) 16 (9.52) 72 (42.86) 80 (47.62) 30.95
CCC (367) 27 (7.36) 155 (42.23) 185 (50.41) 28.47 0.4633 0.4633 0.90 [0.67–1.20]
rs2228570 A|G Asymptomatic (170) 21 (12.35) 75 (44.12) 74 (43.53) 34.41
CCC (372) 69 (16.67) 192 (51.61) 118 (31.72) 42.47 4.46E-03 0.0178 1.51 [1.14–2.00]
Table 3.  Logistic regression analysis of VDR polymorphisms in asymptomatic and chronic Chagas 
cardiomyopathy (CCC) individuals. including age as covariate.
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in Chagas patients. The analysis of vitamin D profiles in individuals exposed to T. cruzi infection with different 
degrees of cardiac involvement would shed light into this idea.
On the other hand, the frequency of the VDR allele rs2228570* A was increased in the seronegative group 
compared to the seropositive one. In principle, this may be contradictory to the above, as a more potent innate 
response should lead to a quicker clearance of the parasite in infected individuals before the production of anti-
bodies. However, the statistical significance of this result was lost after correction for multiple testing, which 
indicates a lack of consistency of this putative association. Further analyses in larger populations are required to 
clarify this issue.
The role of vitamin D in other protozoan infections is not clear. In malaria, for instance, two different studies 
indicated that this molecule plays an important role in the control of the immune pathogenesis and cerebral 
malaria32–34. Vitamin D was observed to reduce the risk of cerebral malaria in mice, thus suggesting that it may 
attenuate the inflammatory response leading to an increase of survival rates32. However, evidences also point to 
vitamin D deficiency as directly responsible for severe cerebral malaria in children coming from Uganda33. To 
our knowledge, only one study has evaluated the possible association between VDR genetic variation and malaria. 
Specifically, two VDR SNPs, rs731236 and rs1544410, were shown to affect gametocytemia levels in individuals 
infected with Plasmodium vivax34. In Leishmania, two different studies indicated that suppression of both vitamin 
D and VDR in mice favor the parasite eradication in a TH1 dependent manner35,36, supporting our hypothesis 
that vitamin D likely promotes parasite clearance in Chagas.
Regarding the study of VDR gene polymorphisms in other infectious diseases, rs2228570 has been associated 
with tuberculosis in populations of different ethnicities, although the results are contradictory. For instance, a 
meta-analysis and a case/control study showed that the rs2228570* A allele conferred risk to this condition in 
Chinese and Iranian patients, respectively37,38. However, other studies reported associations of this same allele 
with protection against pulmonary tuberculosis in a Moroccan population39. VDR rs2228570 has been evaluated 
also in leprosy, an infectious disease caused by another species of Mycobacterium. In this case, homozygosity of 
rs2228570* A was associated with a higher risk to develop leprosy in an Indian population40.
Thus, it seems clear that the vitamin D signaling has a major role in the immune response against different 
infectious diseases, and this has led to propose that controlling the uptake and metabolic status of vitamin D may 
be useful to improve the current therapeutic strategies in these conditions1,41. Consequently, future studies aimed 
to analyze the levels of vitamin D in the different groups of individuals included in this study, could represent an 
important step forward towards the understanding of Chagas disease development and treatment. Replication of 
the genetic results reported here in larger independent cohorts would be also desirable to confirm our findings.
In conclusion, we have observed a genetic association between the VDR gene polymorphism rs2228570 and 
risk to develop CCC in Chagas patients. Although this association has a clear functional implication, more pow-
ered studies and functional experiments are needed to definitively confirm the involvement of the vitamin D 
signaling in the development of this severe complication after infection by T. cruzi.
Material and Methods
Study subjects. For this study, 1,172 individuals from the endemic regions for T. cruzi Guanentina and 
Comunera at the Santander Department, Colombia (localized between 5°26′ and 8°08′ north and 72°26′ and 
74°32′ west) (Supplementary Figure S1) were enrolled. These provinces are located on the north-east side of the 
country, and their population is a homogeneous mix with no specific concentration of any ethnicity. Regarding 
the selection criteria, participants were recruited either after a medical visit to the endemic area or after attending 
to “Fundación Cardiovascular de Colombia”, a medical institution specialized in cardiovascular disorders situated 
in the city of Floridablanca (Supplementary Figure S1), where they were diagnosed with Chagas disease. Almost 
all invited individuals agreed to participate in this study. Since Chagas disease is a chronical disorder in which 
symptoms may appear after several years of infection7,8, we decided to exclude those individuals younger than 
30 years old (189 in total) in order to perform a more consistent analysis of possible resistance to the infection 
(as the selected individuals had a longer time of exposure to vectorial infection). In total, 983 individuals were 
finally included in the analyses. Then, the individuals were classified as seronegative or seropositive (n = 436 
and 547, respectively) for T. cruzi antigens accordingly to two different commercial immunological tests, the 
enzyme-linked immunosorbent assay (ELISA) (BioELISA Chagas, Biokit, Lliçà d’Amunt, Barcelona, Spain) and 
indirect hemagglutination (Chagatest IHA, Wiener Lab, Rosario, Argentina). All seronegative individuals were 
negative for both tests. Seropositive patients underwent an exhaustive clinical evaluation and were subsequently 
subdivided into asymptomatic and chronic Chagas cardiomyopathy (CCC) patients (n = 171 and 376, respec-
tively) based on electrocardiogram and echocardiogram information. This classification is based in the guide-
lines from the World Health Organization (WHO) (http://www.who.int/mediacentre/factsheets/fs340/en/), the 
Pan-American Health Organization (PAHO) (http://www.paho.org/hq/index.php?option=com_topics&view= 
article&id=10&Itemid=40743), and the classification established by the international consensus of Buenos Aires 
of 2010 (http://www.fac.org.ar/7cvc/llave/c016/mordinio.pdf). The mean age of participants was 52.11 years for 
seronegative individuals, 56.67 for asymptomatic individuals and 62.66 for CCC patients. The sex distribution for 
the entire group was 55% female and 45% male.
Ethics statement. All participants signed an informed consent. This study was approved by the Act No. 15 
of 2005 by the Ethics Committees from “Universidad Industrial de Santander” and “Fundación Cardiovascular de 
Colombia” in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
SNP selection. Following a candidate gene strategy, four single-nucleotide polymorphisms (SNPs) of 
the VDR gene, previously described to have a functional implication on gene expression and function, were 
selected for this study22,23,42,43. These variants include rs731236 (Taq1), rs7975232 (Apa1), rs1544410 (Bsm1), and 
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rs2228570 (Fok1). The three first SNPs have been related to a differential expression of VDR in different cells, 
whereas the latter represents a cytosine to thymine change in an ACG codon, which creates an alternative start 
site that produces a longer VDR protein with a reduced transcriptional activity22,23,42,43.
DNA extraction and Genotyping. Genomic DNA was isolated from 5–10 ml of EDTA anticoagulated 
blood samples using standard salting-out techniques as previously described44. The four SNPs were genotyped 
using TaqMan allelic discrimination assays from Applied Biosystems (Foster City, California, USA; catalog 
numbers: C___2404008_10, C__28977635_10, C___8716062_10, C__12060045_20). The genotyping was per-
formed on a LightCycler 480 real-time PCR system (Roche Diagnostics, Basel, Switzerland).
Statistical analysis. All the statistical analyses were performed with the statistical software package Plink 
V1.07 (http://pngu.mgh.harvard.edu/purcell/plink)45. For all groups of individuals, possible deviance from 
Hardy-Weinberg equilibrium was determined in every SNP at the 1% significance level. To test for possible allelic 
and genotypic associations with disease susceptibility and clinical complications, we compared the allelic, gen-
otypic and haplotypic frequencies of the VDR variants between seronegative vs. seropositive individuals and 
asymptomatic vs. CCC individuals by logistic regression assuming an additive model and using age as covariate 
(as in Chagas disease symptoms may appear many years after infection). The Benjamini & Hochberg step-up 
false discovery rate (FDR) correction was used in all analyses to control for possible multiple testing effects. Odds 
ratios (OR) and 95% confidence intervals (CI) were calculated according to Woolf ’s method. P-values lower than 
0.05 were considered as statistically significant. Pairwise linkage disequilibrium (LD) (D’ and r2) and haplotypic 
blocks were estimated using an expectation–maximization algorithm as implemented in Haploview v4.246. The 
statistical power of our study was calculated with the Power Calculator for Genetic Studies 2006 (CaTS) software 
(http://www.sph.umich.edu/csg/abecasis/CaTS/)47.
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